19 May 2016 - Empliciti was approved by the European Commission with additional monitoring on 11 May 2016.

Empliciti indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003967/human_med_001968.jsp&mid=WC0b01ac058001d124